Zinzino Interim Report For Q3 2025

Strong sales growth and increased profit margins drive profitability upwards

To view the full report, go to: Zinzino Interim Report Q3 2025

Revenue for the third quarter of 2025 amounted to SEK 784.1 (532.8) million, corresponding to 47% (22%) growth compared with the same period last year. In local currencies, revenue for the third quarter increased by 53% compared with the corresponding period last year.

EBITDA increased to SEK 109.7 (63.0) million after the EBITDA margin increased to 14.0% (11.8%).

The improved EBITDA margin compared to the corresponding period last year was mainly due to stronger gross profit and increased synergies, primarily related to the acquisition of Zurvita.

During the quarter, Zinzino also acquired the assets of the US-based direct sales companies Bodē Pro and Truvy to increase distribution power in North America, Latin America, South Korea and Japan.

JULY-SEPTEMBER 2025

• Total revenue amounted to SEK 784.1 (532.8) million, corresponding to a growth of 47% (22%)
• Gross profit amounted to SEK 277.2 (178.8) million and the gross profit margin was 35.4% (33.6%)
• EBITDA amounted to SEK 109.7 (63.0) million and the EBITDA margin was 14.0% (11.8%)
• Net profit amounted to SEK 89.4 (42.6) million
• Net profit per share after tax before dilution amounted to SEK 2.47 (1.24)
• Cash flow from operating activities amounted to SEK 136.6 (36.9) million

JANUARY-SEPTEMBER 2025

• Total revenue amounted to SEK 2,302.2 (1,494.3) million, corresponding to a growth of 54% (21%)
• Gross profit amounted to SEK 748.7 (514.1) million and the gross profit margin was 32.5% (34.4%)
• EBITDA amounted to SEK 268.2 (177.8) million and the EBITDA margin was 11.6% (11.9%)
• Net profit amounted to SEK 200.9 (126.1) million
• Net earnings per share after tax before dilution amounted to SEK 5.66 (3.69)
• Cash flow from operating activities amounted to SEK 270.4 (128.3) million
• Cash and cash equivalents on the balance sheet date amounted to SEK 529.2 (321.2) million

EVENTS AFTER THE REPORTING DATE

• Acquisition of Sanki to increase distribution power in North America and South America
• Acquisition of 35% of shares in Xion International Group
• Launch of Gut Health Test

Summary message from Zinzino CEO Dag Bergheim Pettersen:

“Sales growth continues at a high pace with a very strong profitability after strengthened margins in all areas. Growth for the third quarter of 2025 was 47% compared to the third quarter the previous year and accumulated growth was a full 54%. At the same time, the quarter’s EBITDA margin increases to 14.0% compared to 11.8% the previous year. We are thus managing to combine growth with very strong profitability, resulting in a fantastically great quarter…

“We are working on further developing our existing product portfolio while developing new products and services. We recently launched a brand-new test that we call the Gut Health Test. It is many years of scientific studies and research that have now been launched, and we are proud to say that over 60,000 tests were sold in less than a month. This further increases our brand awareness and publicity, as well as helps many new customers to better preventive health. In addition, we are building a database that we can utilize for future research and develop even better products going forward, completely based on data and science.”

To read the full report, please visit: Zinzino Interim Report Q3 2025

SOURCE: Zinzino

About Zinzino

Zinzino AB (publ) (ZZ-B.ST) is a global direct-sales company from Scandinavia specializing in test-based, personalized nutrition and scientific skincare. It is a public limited company with its shares listed on Nasdaq First North Premier Growth Market.

Zinzino’s scientifically proven nutritional supplements are available in more than 100 markets across the world. Zinzino has acquired all assets in the health and wellness companies Enhanzz Global, Truvy, Bodē Pro, Valentus, Zurvita, Xelliss, and Sanki Global. The company co-owns the Cypriot olive oil producer Cleanthi Alpha-Olenic LTD, and owns the Swiss biotech skincare brand HANZZ+HEIDII, as well as the Norwegian research and production units BioActive Foods AS and Faun Pharma AS. The company headquarters are in Gothenburg, Sweden, with additional offices in Europe, Asia, and Australia. For more information, please visit www.zinzino.com